- Conditions
- Benign Renal Tumors, Malignant Renal Tumors
- Interventions
- Laser Tissue Welding Device
- Device
- Lead sponsor
- Laser Tissue Welding, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 404
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Huntington's Disease
- Interventions
- Not listed
- Lead sponsor
- University College, London
- Other
- Eligibility
- 11 Years to 75 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2017
- U.S. locations
- 6
- States / cities
- Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell
- Interventions
- oral rigosertib, cisplatin, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Newark, Delaware • The Bronx, New York + 1 more
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
- Interventions
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
- Drug
- Lead sponsor
- BBB-Therapeutics B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Best Practice, Comparator Program, Best Practice, Usual Care, Internet-Based Intervention, Massage Therapy, Survey Administration
- Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Interdisciplinary Communication, Interpersonal Relations, Adverse Event, Interprofessional Relations
- Interventions
- Advanced and Integrated MicroSystems (AIMS) interventions
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4,265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Pensacola, Florida • Muncie, Indiana • Burlington, North Carolina + 1 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Home-based exercise intervention
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • New York, New York
- Conditions
- Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
- Radiation · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Critical Limb Ischemia, Peripheral Vascular Disease
- Interventions
- Mesendo
- Biological
- Lead sponsor
- TCA Cellular Therapy
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Covington, Louisiana
- Conditions
- Breast Neoplasms
- Interventions
- 9 Peptides from Her-2/neu, CEA, & CTA
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Durvalumab, Stereotactic Body Radiation Therapy (SBRT), Standard of Care Therapy
- Drug · Radiation · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado
- Conditions
- Prostate Cancer Metastatic
- Interventions
- [68Ga]-PSMA-R2
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 2 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsed B-Cell Acute Lymphoblastic Leukemia
- Interventions
- leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
- Procedure · Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Seattle, Washington • Madison, Wisconsin
- Conditions
- Kidney Cancer
- Interventions
- human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2008
- U.S. locations
- 94
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
- Conditions
- Overweight and Obesity
- Interventions
- Experimental: Web-based only (WO) weight intervention, Experimental: WO plus peer-led discussion board (WD), Experimental: WO & professional email counseling (WE)
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 40 Years to 69 Years · Female only
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more
- Conditions
- Huntington's Disease
- Interventions
- No Study Drug was Administered in this Study
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Englewood, Colorado • Washington D.C., District of Columbia • Wichita, Kansas + 3 more
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT
- Drug · Biological · Radiation
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Healthy Volunteers
- Interventions
- GLA-AF, GLA-SE, Squalene
- Drug · Other
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Interventions
- Radiation, Imiquimod, Cyclophosphamide
- Radiation · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Interventions
- CARE, TARE, Home-Based Stretching
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts